Discussion
®
NEUROENDOCRINE TUMOURS
The GRAN-T-MTC study represents a joint effort of the GRAN-T-MTC consortium to develop a diagnostic and potentially therapeutic radiopharmaceutical for imaging of MTC. The results in the present study suggest that the safety profile of the new radiopharmaceutical [In the setting of the first-in-human application of the IMP, evaluation of the safety of the compound was the primary goal. Due to the concern of the potential side effects triggered by the release of Ct by the radiopharmaceutical (analogous to the currently unavailable Pentagastrin® test), Ct concentrations were monitored during and after the application of [Pharmacokinetics of [In comparison to conventional imaging modalities, [Although promising preclinical data are available for several decades on CCK2R imaging in MTC [Theranostic compounds labelled with positron-emitting radionuclides offer several advantages over single-photon labelled alternatives, including inherent tomographic imaging, improved sensitivity, higher spatial resolution, and shorter imaging time, as already demonstrated for somatostatin receptor targeting in neuroendocrine tumours [